The role of the sugar component in cardiac glycosides on their action in patients with auricular fibrillation and congestive failure.
D000328:Adult; D000368:Aged; D001281:Atrial Fibrillation / Q000188:drug therapy*; D002301:Cardiac Glycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004074:Digitoxin / Q000627:therapeutic use; D004077:Digoxin / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D007799:Lanatosides / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
D002301:Cardiac Glycosides; D007799:Lanatosides; D004077:Digoxin; D004074:Digitoxin